Mizuho Securities USA LLC Acquires Shares of 15,800 Teladoc Health Inc (TDOC)

Mizuho Securities USA LLC acquired a new stake in Teladoc Health Inc (NYSE:TDOC) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 15,800 shares of the health services provider’s stock, valued at approximately $1,364,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Empowered Funds LLC acquired a new stake in Teladoc Health in the 3rd quarter valued at about $1,856,000. Bank of Montreal Can increased its position in Teladoc Health by 41.4% in the 3rd quarter. Bank of Montreal Can now owns 20,565 shares of the health services provider’s stock valued at $1,776,000 after acquiring an additional 6,019 shares in the last quarter. We Are One Seven LLC acquired a new stake in Teladoc Health in the 3rd quarter valued at about $225,000. Atria Investments LLC acquired a new stake in Teladoc Health in the 3rd quarter valued at about $228,000. Finally, Barometer Capital Management Inc. acquired a new stake in Teladoc Health in the 3rd quarter valued at about $6,519,000.

Teladoc Health stock traded down $1.72 during midday trading on Thursday, hitting $68.23. 1,213,800 shares of the stock were exchanged, compared to its average volume of 1,277,708. Teladoc Health Inc has a 52 week low of $27.30 and a 52 week high of $89.05. The firm has a market capitalization of $6.01 billion, a price-to-earnings ratio of -42.81 and a beta of 0.57. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.14 and a quick ratio of 3.14.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, August 1st. The health services provider reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.01. Teladoc Health had a negative net margin of 37.78% and a negative return on equity of 19.10%. The business had revenue of $94.60 million for the quarter, compared to analyst estimates of $91.56 million. During the same quarter last year, the firm earned ($0.28) EPS. Teladoc Health’s quarterly revenue was up 112.1% compared to the same quarter last year. As a group, analysts predict that Teladoc Health Inc will post -1.51 EPS for the current fiscal year.

In other Teladoc Health news, CEO Jason N. Gorevic sold 25,000 shares of Teladoc Health stock in a transaction that occurred on Thursday, August 16th. The shares were sold at an average price of $71.66, for a total value of $1,791,500.00. Following the transaction, the chief executive officer now owns 561,184 shares of the company’s stock, valued at $40,214,445.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Mark Hirschhorn sold 35,000 shares of Teladoc Health stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $80.42, for a total transaction of $2,814,700.00. Following the completion of the transaction, the vice president now directly owns 10,000 shares in the company, valued at approximately $804,200. The disclosure for this sale can be found here. Insiders have sold a total of 131,706 shares of company stock worth $9,953,679 in the last three months. 3.95% of the stock is owned by insiders.

TDOC has been the topic of several recent research reports. KeyCorp raised their target price on shares of Teladoc Health from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Friday, September 28th. SunTrust Banks raised their target price on shares of Teladoc Health to $100.00 and gave the company a “buy” rating in a research note on Monday, September 24th. Oppenheimer raised their target price on shares of Teladoc Health from $68.00 to $89.00 and gave the company an “outperform” rating in a research note on Friday, September 28th. Citigroup reaffirmed a “buy” rating and issued a $95.00 target price on shares of Teladoc Health in a research note on Friday, September 28th. Finally, Piper Jaffray Companies raised their target price on shares of Teladoc Health to $84.00 and gave the company an “overweight” rating in a research note on Friday, September 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $81.95.

About Teladoc Health

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Recommended Story: What are earnings reports?

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply